The cost of lung cancer in Alberta

Canadian Respiratory Journal

Volumn 14, Issue 2, 2007, Pages 81-86

  Demeter, Sandor J ^a,d   Jacobs, Philip ^b   Chmielowiec, Chester ^c   Logus, Wayne ^c   Hailey, David ^b   Fassbender, Konrad ^b   McEwan, Alexander ^c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d Health Science Centre   (Canada)

Author keywords

Administrative medicine; Health economics; Lung neoplasm; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT;

AMBULATORY CARE; ARTICLE; CANADA; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITAL ADMISSION; HUMAN; LABORATORY TEST; LUNG CANCER; LUNG NON SMALL CELL CANCER; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SMALL CELL CARCINOMA;

EID: 34248326881     PISSN: 11982241     EISSN: None     Source Type: Journal    
DOI: 10.1155/2007/847604     Document Type: Article

References (20)

1. National Cancer Institute of Canada. Canadian cancer statistics 2004. (Version current at October 17, 2006).
2. Government of Canada. Economic burden of illness in Canada, 1998. (Version current at October 17, 2006).
3. Evans WK, Will BP, Berthelot JM, Wolfson MC. Estimating the cost of lung cancer diagnosis and treatment in Canada: The POHEM model. Can J Oncol 1995;5:408-19.
4. Evans WK, Will BP, Berthelot JM, Wolfson MC. The economics of lung cancer management in Canada. Lung Cancer 1996;14:19-29.
5. Evans WK, Will BP, Berthelot JM, Earle CC. Cost of combined modality interventions for stage III non-small-cell lung cancer. J Clin Oncol 1997;15:3038-48.
6. Evans WK. Cost-effectiveness of gemcitabine in stage IV non-small-cell lung cancer: An estimate using the Population Health Model lung cancer module. Semin Oncol 1997;24(2 Suppl 7):S7-56-S7-63.
7. Earle CC, Evans WK. Cost-effectiveness of paclitaxel plus cisplatin in advanced non-small-cell lung cancer. Br J Cancer 1999;80:815-20.
8. Jaakkimainen L, Goodwin PJ, Paster J, Warde P, Murray N, Rapp E. Counting the cost of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990;8:1301-9.
9. Coy P, Schaafsma J, Schofield J. The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48:1025-33.
10. Oliver E, Killen J, Kiebert G, et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax 2001;56:785-90.
11. Rosenthal MA, Webster PJ, Gebski VJ, Stuart-Harris RC, Langlands AO, Boyages J. The cost of treating small cell lung cancer. Med J Aust 1992;156:605-10.
12. Esnaola NF, Lazarides SN, Mentzer SJ, Kuntz KM. Outcomes and cost-effectiveness of alternate staging strategies for non-small-cell lung cancer. J Clin Oncol 2002;20:263-73.
13. Vergnenegre A, Molinier L, Chouaid C. Economic analyses and lung cancer. Monaldi Arch Chest Dis 2001;56:336-43.
14. Demeter SJ, Chmielowiec C, Logus W, et al. The descriptive epidemiology of primary lung cancer in an Alberta cohort with a multivariate analysis of survival to two years. Can Resp J 2003;10:435-41.
15. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7.
16. National Cancer Institute. Non-small cell lung cancer (PDQ®): Treatment. (Version current at October 17, 2006).
17. National Cancer Institute. Small cell lung cancer (PDQ®): Treatment. (Version current at October 17, 2006).
18. Fassbender K, Fainsinger R, Brenneis C, Brown P, Braun T, Jacobs P. Utilization and costs of the introduction of system-wide palliative care in Alberta, 1993 - 2000. Palliative Medicine 2005;19:513-20.
19. Etzioni R, Riley GF, Ramsey SD, Brown M. Measuring costs: Administrative claims data, clinical trials, and beyond. Med Care 2002;40:III63-72.
20. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics 1997;53:419-34.